While the ultimate goal of the BRAIN Initiative and Bioelectronic Medicine (Galvani Bioelectronics, Neuralink, Kernel, and others) is to understand brain function and treat neurological disease, the critical hurdle in basic neuroscience is placed on the unreliable neuroelectronic interfaces over relevant time scales and the limited understanding within the neural interfacing field. A search on Google Scholar reveals the magnitude of the disparity in research output: "neuroscience" returns 3.99 million articles and "MEMS" approximately 1.3 million, whereas "neural interfaces" yields only around 24,200 articles. This ~160-fold gap in publication volume relative to neuroscience reflects a structural deficit in research capacity: too few scientists, engineers, and clinicians have received specialized education and multidisciplinary training in the intersection of these fields.

The commercial stakes underscore the urgency. Morgan Stanley's 2024 report "Brain-Computer Interface Primer: The Next Big MedTech Opportunity?" estimates the U.S. BCI market could reach a total addressable market (TAM) of $400 billion. Yahoo Finance The report partitions this TAM into two epochs: an early TAM of $80 billion covering individuals with critical impairments (approximately 2.8 million U.S. patients), and an intermediate TAM of $320 billion for follow-on adopters, with BCI commercialization, including product launch and reimbursement, projected within five years. Neurotechreports Near-term revenue projections are more measured, with analysts forecasting just under $1.5 billion in implant revenues through 2035 and an annual run-rate exceeding $500 million by 2036, with penetration estimated at less than 3% by 2045. Yahoo Finance The gap between a $400 billion TAM and sub-3% penetration over two decades is itself a quantitative argument for the field's central unsolved problem: biological interface reliability.

Consequences of limited researcher capacity translate directly into constrained diversity of opinion and perspective, as well as the unchecked spread of prevailing theory and the suppression of minority views. A prominent example is the dogma, stated explicitly in the literature, "that it is impossible to activate a set of cells restricted to a small spatial volume" (Neuron 63, 508-522, 2009). While this claim is rooted in a seminal study, we demonstrate that it rests on results evaluated under a restricted stimulation parameter space, and does not hold when that space is adequately explored. This is precisely the kind of error that propagates when the investigator community is too small and too homogeneous to subject foundational claims to genuine empirical stress-testing. As NSF has stated, "Diversity of thought, perspective, and experience is essential to achieving excellence in 21st century science and engineering research and education" (NSF 16-048). Multidisciplinary training spanning neuroscience, engineering, and clinical medicine is necessary, as is diversity of approach rooted in diversity of cultural and socioeconomic background, which introduces problem framings and experimental strategies that monocultures of training systematically miss.

Supported by NSF CAREER 1943906